The FDA approval of Selarsdi 130 mg/26 ml in a single-dose vial for intravenous infusion expands the label to include ...

The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's ...

Alvotech (ALVO) has released an update. Alvotech and Teva Pharmaceuticals have received U.S. FDA approval for a new intravenous presentation of ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to ...

Teva (TEVA) and Alvotech (ALVO) said the FDA has expanded labeling for its biosimilar of Stelara to include the treatment of ...

Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the FDA has ...

New York, October 22, 2024 - Nodenza Venture Partners ("Nodenza”), today announces its investment in Trellis Bioscience ("Trellis”), a clinical-stage company focused on discovering and developing ...

In April 2024, Teva and Alvotech won the FDA’s approval for Selarsdi, their Stelara copycat for psoriatic arthritis and plaque psoriasis. Selarsdi, however, is not approved for Crohn’s disease and ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations ...

Additional approved biosimilars include Alvotech and Teva Pharmaceuticals’ Selarsdi (ustekinumab-aekn) and Fresenius Kabi and Formycon’s Otulfi (ustekinumab-aauz). The latter became the fourth ...